In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
Gian Matteo Rigolin, Antonio Cuneo(Arcispedale Sant'Anna), Maria Antonella Bardi(Arcispedale Sant'Anna), Maurizio Cavallari(Arcispedale Sant'Anna), Elisa Tammiso(Arcispedale Sant'Anna), Elena Saccenti(University of Ferrara), Francesco Cavazzini(Arcispedale Sant'Anna), Danilo Faraci(Arcispedale Sant'Anna), Laura Lupini(University of Ferrara), Aurora Melandri(Arcispedale Sant'Anna), Antonio Urso(Arcispedale Sant'Anna), Enrico Lista(Arcispedale Sant'Anna), Carmine Liberatore(Arcispedale Sant'Anna), Francesca Maria Quaglia(University of Verona), Eleonora Volta(Arcispedale Sant'Anna), Emanuele Guardalben(Arcispedale Sant'Anna), Cristian Bassi(University of Ferrara), Massimo Negrini(University of Ferrara), Luca Formigaro(Arcispedale Sant'Anna)
Cited by 99
Related Papers
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Isolation and characterization of CD146+ multipotent mesenchymal stromal cells
|Experimental Hematology|2008|254
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
|Blood|2015|215
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
|Blood|2019|215
Oncogenic Role of <i>miR-483-3p</i> at the <i>IGF2/483</i> Locus
|Cancer Research|2010|213